| 1 |
Sala V, Della Sala A, Hirsch E, et al. Signaling pathways underlying anthracycline cardiotoxicity [J]. Antioxid Redox Signal, 2020, 32(15): 1098-1114.
|
| 2 |
Dyhl-Polk A, Vaage-Nilsen M, Schou M, et al. Incidence and risk markers of 5-fluorouracil and capecitabine cardiotoxicity in patients with colorectal cancer [J]. Acta Oncol, 2020, 59(4): 475-483.
|
| 3 |
Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations [J]. Ann Oncol, 2020, 31(2): 171-190.
|
| 4 |
Herrmann J. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia [J]. Nat Rev Cardiol, 2020, 17(8): 474-502.
|
| 5 |
关旭敏, 刘基巍, 夏云龙. 2019 AHA肿瘤心脏病学之血管和代谢观点科学声明解读 [J]. 中国循环杂志, 2019, 34(z1): 101-107.
|
| 6 |
Sawicki K T, Sala V, Prever L, et al. Preventing and treating anthracycline cardiotoxicity: new insights [J]. Annu Rev Pharmacol Toxicol, 2020, 6(61): 309-332.
|
| 7 |
čelutkienė J, Pudil R, López Fernández T, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of role of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC) [J]. Eur J Heart Fail, 2020, 22(9): 1504-1524.
|
| 8 |
Yeo JH, Ahn H, Park I, et al. Left ventricular ejection fraction (LVEF) change for the first 6 months predicts development of trastuzumab-related cardiotoxicity in patients with breast cancer: An implication for the more efficient cardiac surveillance [J]. Ann Oncol, 2018, 29(suppl 8): 613.
|
| 9 |
Upshaw JN, Finkelman B, Hubbard RA, et al. Comprehensive assessment of changes in left ventricular diastolic function with contemporary breast cancer therapy [J]. JACC Cardiovasc Imaging, 2020, 13(1 Pt 2): 198-210.
|
| 10 |
Mawad W, Mertens L, Pagano JJ, et al. Effect of anthracycline therapy on myocardial function and markers of fibrotic remodelling in childhood cancer survivors [J]. Eur Heart J Cardiovasc Imaging, 2020, 22(4): 435-442.
|
| 11 |
Venturelli F, Masetti R, Fabi M, et al. Tissue Doppler imaging for anthracycline cardiotoxicity monitoring in pediatric patients with cancer [J]. Cardiooncology, 2018, 4: 6.
|
| 12 |
Lambert J, Lamacie M, Thampinathan B, et al. Variability in echocardiography and MRI for detection of cancer therapy cardiotoxicity [J]. Heart, 2020, 106(11): 817-823.
|
| 13 |
Alam S, Chandra S, Saran M, et al. To study the usefulness and comparison of myocardial strain imaging by 2D and 3D echocardiography for early detection of cardiotoxicity in patients undergoing cardiotoxic chemotherapy [J]. Indian Heart J, 2019, 71(6): 468-475.
|
| 14 |
Zhang KW, Finkelman BS, Gulati G, et al. Abnormalities in 3-Dimensional left ventricular mechanics with anthracycline chemotherapy are associated with systolic and diastolic dysfunction [J]. JACC Cardiovasc Imaging, 2018, 11(8): 1059-1068.
|
| 15 |
Porter TR, Mulvagh SL, Abdelmoneim SS, et al. Clinical applications of ultrasonic enhancing agents in echocardiography: 2018 American Society of Echocardiography Guidelines Update [J]. J Am Soc Echocardiogr, 2018, 31(3): 241-274.
|
| 16 |
Karagodin I, Genovese D, Kruse E, et al. Contrast-enhanced echocardiographic measurement of longitudinal strain: accuracy and its relationship with image quality [J]. Int J Cardiovasc Imaging, 2020, 36(3): 431-439.
|
| 17 |
Mahjoob MP, Sheikholeslami SA, Dadras M, et al. Prognostic value of cardiac biomarkers assessment in combination with myocardial 2D strain echocardiography for early detection of anthracycline-related cardiac toxicity [J]. Cardiovasc Hematol Disord Drug Targets, 2020, 20(1): 74-83.
|
| 18 |
Wang B, Yu Y, Zhang Y, et al. Speckle tracking echocardiography in the early detection and prediction of anthracycline cardiotoxicity in diffuse large B-cell lymphoma treated with (R)-CHOP regimen [J]. Echocardiography, 2020, 37(3): 421-428.
|
| 19 |
Demissei BG, Fan Y, Qian Y, et al. Left ventricular segmental strain and the prediction of cancer therapy-related cardiac dysfunction [J]. Eur Heart J Cardiovasc Imaging, 2020, 22(4): 418-426.
|
| 20 |
Chang WT, Feng YH, Kuo YH, et al. Layer-specific distribution of myocardial deformation from anthracycline-induced cardiotoxicity in patients with breast cancer-From bedside to bench [J]. Int J Cardiol, 2020, 311: 64-70.
|
| 21 |
Coutinho CM, Moura BL, Portugal G, et al. Three-dimensional speckle-tracking echocardiography for the global and regional assessments of left ventricle myocardial deformation in breast cancer patients treated with anthracyclines [J]. Clin Res Cardiol, 2020, 109(6): 673-684.
|
| 22 |
Chen J, Wang L, Wu FF, et al. Early detection of cardiotoxicity by 3D speckle tracking imaging of area strain in breast cancer patients receiving chemotherapy [J]. Echocardiography, 2019, 36(9): 1682-1688.
|
| 23 |
Mihalcea D, Florescu M, Bruja R, et al. 3D echocardiography, arterial stiffness, and biomarkers in early diagnosis and prediction of CHOP-induced cardiotoxicity in non-Hodgkin's lymphoma [J]. Sci Rep, 2020, 10(1): 18473.
|
| 24 |
Salas-Mera D, Deiros-Bronte L, Uceda-Galiano A, et al. Chemotherapy-induced cardiotoxicity in adolescent after heart transplant: do not forget the right ventricle [J]. Pediatr Cardiol, 2019, 40(8): 1756-1758.
|
| 25 |
Radu L, Ghiorghiu I, Oprescu A, et al. Cardiotoxicity evaluation in pediatric patients with acute lymphoblastic leukemia-results of prospective study [J]. Med Ultrason, 2019, 21(4): 449-455.
|
| 26 |
韩若凌, 尹笑笑, 赵娜. Tei指数评价蒽环类药物对恶性肿瘤患儿的右心损害 [J/CD]. 中华医学超声杂志(电子版), 2018, 15(6): 433-439.
|
| 27 |
Keramida K, Farmakis D, Bingcang J, et al. Longitudinal changes of right ventricular deformation mechanics during trastuzumab therapy in breast cancer patients [J]. Eur J Heart Fail, 2019, 21(4): 529-535.
|
| 28 |
Wang Y, Lu C, Li H, et al. 3D-STI evaluation of the effect of dexrazoxane on the mechanical properties of right ventricular myocardium in breast cancer patients treated with pirarubicin [J]. Ann Palliat Med, 2020, 9(3): 1187-1197.
|